Over the latest trailing 12-month period, total return cagr is -75.96%. The comparable SPY value is +16.94%. Year-to-date total return is -52.48%. Total return includes price appreciation and reinvested dividends.
Over longer horizons, Total Return CAGR averages -68.83% over 3 years and -64.14% over 5 years; the trailing 12 months came in at -75.96%. Total return includes dividends reinvested. The total return CAGR includes both price appreciation and dividends reinvested. This gives a more complete picture of the company's investment performance.
Traws Pharma, Inc. (TRAW)
Total Return growth vs the same calendar quarter one year earlier, last 39 comparable quarters.
Quarter-end value of $100 invested at the start of the available history, with dividends reinvested; the newest quarter may be quarter-to-date. Q4 2026 (2026-10-05): $0.00.
| Year | Total return for the year |
|---|---|
| 2026 (YTD) | -52.48% |
| 2025 | -87.28% |
| 2024 | -52.65% |
| 2023 | +15.42% |
| 2022 | -74.51% |
| 2021 | -63.83% |
| 2020 | +23.68% |
| 2019 | -81.99% |
| 2018 | -90.62% |
| 2017 | -33.92% |
| 2016 | -76.35% |
| 2015 | -70.82% |
| 2014 | -71.34% |
| Period | Period End | QoQ Return | YoY Return |
|---|---|---|---|
| Q4 2026 (QTD) | 2026-10-05 | N/A | N/A |
| Q3 2026 | 2026-09-25 | N/A | N/A |
| Q2 2026 | 2026-06-25 | N/A | N/A |
| Q1 2026 | 2026-03-30 | N/A | N/A |
| Q4 2025 | 2025-12-31 | N/A | N/A |
| Q3 2025 | 2025-09-30 | N/A | N/A |
| Q2 2025 | 2025-06-30 | N/A | N/A |
| Q1 2025 | 2025-03-27 | N/A | -88.3% |
| Q4 2024 | 2024-12-27 | N/A | N/A |
| Q3 2024 | 2024-09-26 | N/A | N/A |
| Q2 2024 | 2024-06-26 | -49.9% | -62.6% |
| Q1 2024 | 2024-03-25 | N/A | N/A |
| Q4 2023 | 2023-12-27 | N/A | N/A |
| Q3 2023 | 2023-09-26 | -38.1% | -22.3% |
| Q2 2023 | 2023-06-30 | N/A | -11.3% |
| Q1 2023 | 2023-03-29 | N/A | -60.8% |
Calendar returns: QoQ compares the prior calendar quarter; YoY compares the same calendar quarter a year earlier. The newest quarter is in progress (quarter-to-date).
